Resources

03.12.2024

Bringing a new drug to market is a complex and lengthy process that involves multiple phases of research, development, testing, and regulatory hurdles. Venture capital plays a critical role in each phase.

02.14.2024

Read Incubate's blog on the recently announced March-In proposal.

02.07.2024

Incubate is an international coalition of life science venture capitalists committed to educating policymakers on the role of venture capital in bringing promising, innovative treatments to patients in need.

02.06.2024

02.01.2024

This bipartisan legislation would eliminate the small-molecule penalty by aligning the price-setting timeline for small and large molecule medicines.

01.24.2024

An Open Letter to Members of Congress and the Biden Administration from Leaders in the Life Sciences Community As leaders...

01.21.2024

Incubate and DLA Piper hosted a breakfast panel at this year's J.P. Morgan Healthcare Conference in San Francisco, California.

12.07.2023

Discussion on the vital role of M&A in bringing the next generation of biopharmaceutical breakthroughs to patients.

12.07.2023

After a nine-month review, the Biden administration has reached the unprecedented and misguided conclusion that the 1980 Bayh-Dole Act gives it the authority to impose de facto price controls on drugs developed with federal research funding.

11.20.2023

Incubate and DLA Piper invite you to join us on the morning of Sunday, January 7th, as part of JPM Week 2024.

10.12.2023

Incubate Executive Director John Stanford sat down this week with Mary R. Grealy, CEO of the Healthcare Leadership Council, to discuss the latest developments in health policy on the Making Medicine podcast.

09.26.2023

Fitch Ratings recently released an analysis showing that Medicare's drug price negotiation program is expected to deter investments into small molecule drugs.